{ "version": "2.2", "instance": { "ea0304033-6k_clearmind.htm ea030403301ex99-1.htm": { "nsprefix": "cmnd", "nsuri": "http://clearmindmedicine.com/20260731", "dts": { "schema": { "local": [ "cmnd-20260731.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd" ] }, "calculationLink": { "local": [ "cmnd-20260731_cal.xml" ] }, "definitionLink": { "local": [ "cmnd-20260731_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "cmnd-20260731_lab.xml" ] }, "presentationLink": { "local": [ "cmnd-20260731_pre.xml" ] }, "inline": { "local": [ "ea0304033-6k_clearmind.htm", "ea030403301ex99-1.htm" ] } }, "keyStandard": 144, "keyCustom": 89, "axisStandard": 14, "axisCustom": 0, "memberStandard": 19, "memberCustom": 46, "hidden": { "total": 108, "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 77, "http://clearmindmedicine.com/20260731": 26, "http://xbrl.sec.gov/dei/2025": 5 }, "contextCount": 260, "entityCount": 1, "segmentCount": 72, "elementCount": 419, "unitCount": 9, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 506, "http://xbrl.sec.gov/dei/2025": 10 }, "report": { "R1": { "role": "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation", "longName": "995300 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "cref_55821411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0304033-6k_clearmind.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0304033-6k_clearmind.htm", "first": true, "unique": true } }, "R2": { "role": "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited", "longName": "995301 - Statement - Condensed Interim Consolidated Statements of Financial Position (Unaudited)", "shortName": "Condensed Interim Consolidated Statements of Financial Position (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "cref_817131922", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_817131922", "name": "ifrs-full:OtherCurrentReceivables", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R3": { "role": "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "longName": "995302 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "cref_1650163249", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_1650163249", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R4": { "role": "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParentheticals", "longName": "995303 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)", "shortName": "Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "cref_188062864", "name": "cmnd:ReverseSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": null }, "R5": { "role": "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited", "longName": "995304 - Statement - Condensed Interim Statements of Changes in Shareholders\u2019 Equity (Unaudited)", "shortName": "Condensed Interim Statements of Changes in Shareholders\u2019 Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "cref_1931783238", "name": "ifrs-full:Equity", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_1931783238", "name": "ifrs-full:Equity", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R6": { "role": "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnauditedParentheticals", "longName": "995305 - Statement - Condensed Interim Statements of Changes in Shareholders\u2019 Equity (Unaudited) (Parentheticals)", "shortName": "Condensed Interim Statements of Changes in Shareholders\u2019 Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "cref_188062864", "name": "cmnd:ReverseSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited", "longName": "995306 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Interim Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:ProfitLoss", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:AdjustmentsForAmortisationExpense", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R8": { "role": "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcern", "longName": "995307 - Disclosure - Nature of Operations and Going Concern", "shortName": "Nature of Operations and Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfGoingConcernExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfGoingConcernExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R9": { "role": "http://clearmindmedicine.com/20260731/role/MaterialAccountingPolicyInformation", "longName": "995308 - Disclosure - Material Accounting Policy Information", "shortName": "Material Accounting Policy Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R10": { "role": "http://clearmindmedicine.com/20260731/role/ShortTermInvestments", "longName": "995309 - Disclosure - Short-Term Investments", "shortName": "Short-Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R11": { "role": "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactions", "longName": "995310 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R12": { "role": "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilities", "longName": "995311 - Disclosure - Derivative Warrant Liabilities", "shortName": "Derivative Warrant Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R13": { "role": "http://clearmindmedicine.com/20260731/role/ConvertibleLoans", "longName": "995312 - Disclosure - Convertible Loans", "shortName": "Convertible Loans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R14": { "role": "http://clearmindmedicine.com/20260731/role/ShareCapital", "longName": "995313 - Disclosure - Share Capital", "shortName": "Share Capital", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R15": { "role": "http://clearmindmedicine.com/20260731/role/Warrants", "longName": "995314 - Disclosure - Warrants", "shortName": "Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "cref_55821411", "name": "cmnd:DisclosureOfWarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "cmnd:DisclosureOfWarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R16": { "role": "http://clearmindmedicine.com/20260731/role/StockOptions", "longName": "995315 - Disclosure - Stock Options", "shortName": "Stock Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R17": { "role": "http://clearmindmedicine.com/20260731/role/RestrictedShareUnits", "longName": "995316 - Disclosure - Restricted Share Units", "shortName": "Restricted Share Units", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "cref_55821411", "name": "cmnd:DisclosureOfRestrictedShareUnitsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "cmnd:DisclosureOfRestrictedShareUnitsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R18": { "role": "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagement", "longName": "995317 - Disclosure - Financial Instruments and Risk Management", "shortName": "Financial Instruments and Risk Management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R19": { "role": "http://clearmindmedicine.com/20260731/role/CapitalManagement", "longName": "995318 - Disclosure - Capital Management", "shortName": "Capital Management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R20": { "role": "http://clearmindmedicine.com/20260731/role/SegmentedInformation", "longName": "995319 - Disclosure - Segmented Information", "shortName": "Segmented Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R21": { "role": "http://clearmindmedicine.com/20260731/role/Commitments", "longName": "995320 - Disclosure - Commitments", "shortName": "Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R22": { "role": "http://clearmindmedicine.com/20260731/role/SubsequentEvents", "longName": "995321 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R23": { "role": "http://clearmindmedicine.com/20260731/role/AccountingPoliciesbyPolicyPolicies", "longName": "996322 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "cref_55821411", "name": "cmnd:DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "cmnd:DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R24": { "role": "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsTables", "longName": "996323 - Disclosure - Short-Term Investments (Tables)", "shortName": "Short-Term Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "cref_55821411", "name": "cmnd:DisclosureofFairValueofCommonSharesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "cmnd:DisclosureofFairValueofCommonSharesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R25": { "role": "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsTables", "longName": "996324 - Disclosure - Related Party Transactions (Tables)", "shortName": "Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R26": { "role": "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesTables", "longName": "996325 - Disclosure - Derivative Warrant Liabilities (Tables)", "shortName": "Derivative Warrant Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R27": { "role": "http://clearmindmedicine.com/20260731/role/ConvertibleLoansTables", "longName": "996326 - Disclosure - Convertible Loans (Tables)", "shortName": "Convertible Loans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R28": { "role": "http://clearmindmedicine.com/20260731/role/WarrantsTables", "longName": "996327 - Disclosure - Warrants (Tables)", "shortName": "Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "cref_55821411", "name": "cmnd:DisclosureOfChangesInWarrantsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "cmnd:DisclosureOfWarrantsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "cmnd:DisclosureOfChangesInWarrantsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "cmnd:DisclosureOfWarrantsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R29": { "role": "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsTables", "longName": "996328 - Disclosure - Restricted Share Units (Tables)", "shortName": "Restricted Share Units (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "cref_55821411", "name": "cmnd:ScheduleOfChangesInRSUsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "cmnd:DisclosureOfRestrictedShareUnitsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "cmnd:ScheduleOfChangesInRSUsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "cmnd:DisclosureOfRestrictedShareUnitsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R30": { "role": "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementTables", "longName": "996329 - Disclosure - Financial Instruments and Risk Management (Tables)", "shortName": "Financial Instruments and Risk Management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R31": { "role": "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails", "longName": "996330 - Disclosure - Nature of Operations and Going Concern (Details)", "shortName": "Nature of Operations and Going Concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "cref_55821411", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfGoingConcernExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "dei:EntityIncorporationDateOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfGoingConcernExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R32": { "role": "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "longName": "996331 - Disclosure - Short-Term Investments (Details)", "shortName": "Short-Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "cref_1890108910", "name": "cmnd:StockholdersEquityReverseStockSplits", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "tbody", "table", "cmnd:DisclosureofFairValueofCommonSharesExplanatory", "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_1890108910", "name": "cmnd:StockholdersEquityReverseStockSplits", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "tbody", "table", "cmnd:DisclosureofFairValueofCommonSharesExplanatory", "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R33": { "role": "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails", "longName": "996332 - Disclosure - Short-Term Investments - Schedule of Short-Term Investments (Details)", "shortName": "Short-Term Investments - Schedule of Short-Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "cref_2056552209", "name": "ifrs-full:CurrentInvestments", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_1266948982", "name": "ifrs-full:CurrentInvestments", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "cmnd:DisclosureofFairValueofCommonSharesExplanatory", "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R34": { "role": "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsDetails", "longName": "996333 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:ProportionOfVotingRightsHeldInJointVenture", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "ifrs-full:ProportionOfVotingRightsHeldInJointVenture", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R35": { "role": "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails", "longName": "996334 - Disclosure - Related Party Transactions - Schedule of Compensation to Key Management Personnel for Services (Details)", "shortName": "Related Party Transactions - Schedule of Compensation to Key Management Personnel for Services (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "cref_1042248583", "name": "cmnd:KeyManagementPersonnelCompensationConsultingFees", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_1042248583", "name": "cmnd:KeyManagementPersonnelCompensationConsultingFees", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R36": { "role": "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofBalanceswithRelatedPartiesDetails", "longName": "996335 - Disclosure - Related Party Transactions - Schedule of Balances with Related Parties (Details)", "shortName": "Related Party Transactions - Schedule of Balances with Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "cref_817131922", "name": "ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_808130015", "name": "ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R37": { "role": "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails", "longName": "996336 - Disclosure - Derivative Warrant Liabilities (Details)", "shortName": "Derivative Warrant Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "cref_1650163249", "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_752030340", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "uref_1875399665", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R38": { "role": "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails", "longName": "996337 - Disclosure - Derivative Warrant Liabilities - Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability (Details)", "shortName": "Derivative Warrant Liabilities - Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "cref_1239684291", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "td", "tr", "tbody", "table", "ix:continuation", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_1239684291", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "td", "tr", "tbody", "table", "ix:continuation", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R39": { "role": "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetails", "longName": "996338 - Disclosure - Derivative Warrant Liabilities - Schedule of Changes in the Derivative Warrant Liability (Details)", "shortName": "Derivative Warrant Liabilities - Schedule of Changes in the Derivative Warrant Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "cref_1650163249", "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_1820986407", "name": "ifrs-full:ProceedsFromExerciseOfWarrants", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "tbody", "table", "ix:continuation", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R40": { "role": "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "longName": "996339 - Disclosure - Convertible Loans (Details)", "shortName": "Convertible Loans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "cref_817131922", "name": "cmnd:AggregatePurchasePrice", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_202846384", "name": "cmnd:PercentageOfSubscriptionAmount", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R41": { "role": "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails", "longName": "996340 - Disclosure - Convertible Loans - Schedule of Fair Value of the Promissory Notes (Details)", "shortName": "Convertible Loans - Schedule of Fair Value of the Promissory Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "cref_2056552209", "name": "cmnd:ConvertibleLoan", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_473238819", "name": "ifrs-full:ProceedsFromCurrentBorrowings", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R42": { "role": "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails", "longName": "996341 - Disclosure - Share Capital (Details)", "shortName": "Share Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "cref_55821411", "name": "cmnd:PromissoryNotesConvertedIntoCommonShares", "unitRef": "uref_1875399665", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "cmnd:PromissoryNotesConvertedIntoCommonShares", "unitRef": "uref_1875399665", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R43": { "role": "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofChangesinWarrantsDetails", "longName": "996342 - Disclosure - Warrants - Schedule of Changes in Warrants (Details)", "shortName": "Warrants - Schedule of Changes in Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "cref_589450556", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "cmnd:DisclosureOfWarrantsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_396552747", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "cmnd:DisclosureOfWarrantsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R44": { "role": "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails", "longName": "996343 - Disclosure - Warrants - Schedule of Warrants Outstanding (Details)", "shortName": "Warrants - Schedule of Warrants Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "cref_1820986407", "name": "cmnd:NumberOfWarrantOutstanding", "unitRef": "uref_1875399665", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "tbody", "table", "ix:continuation", "cmnd:DisclosureOfWarrantsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_1820986407", "name": "cmnd:NumberOfWarrantOutstanding", "unitRef": "uref_1875399665", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "tbody", "table", "ix:continuation", "cmnd:DisclosureOfWarrantsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R45": { "role": "http://clearmindmedicine.com/20260731/role/StockOptionsDetails", "longName": "996344 - Disclosure - Stock Options (Details)", "shortName": "Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "cref_1967498480", "name": "cmnd:PercentageOfIssuedAndOutstandingCommonShares", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_1967498480", "name": "cmnd:PercentageOfIssuedAndOutstandingCommonShares", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R46": { "role": "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails", "longName": "996345 - Disclosure - Restricted Share Units (Details)", "shortName": "Restricted Share Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "cref_1571891166", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "uref_1875399665", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "cmnd:DisclosureOfRestrictedShareUnitsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_1432532183", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "uref_1875399665", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "link:footnote", "span", "td", "tr", "tbody", "table", "ix:continuation", "cmnd:DisclosureOfRestrictedShareUnitsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R47": { "role": "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails", "longName": "996346 - Disclosure - Restricted Share Units - Schedule of RSUs (Details)", "shortName": "Restricted Share Units - Schedule of RSUs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "cref_2083825308", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "uref_1875399665", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "cmnd:DisclosureOfRestrictedShareUnitsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_1566953184", "name": "cmnd:WeightedAverageIssuePrice", "unitRef": "uref_983925672", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "cmnd:DisclosureOfRestrictedShareUnitsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R48": { "role": "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementDetails", "longName": "996347 - Disclosure - Financial Instruments and Risk Management (Details)", "shortName": "Financial Instruments and Risk Management (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "cref_55821411", "name": "cmnd:ForeignCurrencyPercentage", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "p", "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "cmnd:ForeignCurrencyPercentage", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "p", "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R49": { "role": "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "longName": "996348 - Disclosure - Financial Instruments and Risk Management - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "shortName": "Financial Instruments and Risk Management - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "cref_817131922", "name": "ifrs-full:CurrentWarrantLiability", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_684384017", "name": "ifrs-full:DebtSecurities", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R50": { "role": "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails", "longName": "996349 - Disclosure - Financial Instruments and Risk Management - Schedule of Foreign Currency Against the Functional Currencies (Details)", "shortName": "Financial Instruments and Risk Management - Schedule of Foreign Currency Against the Functional Currencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "cref_817131922", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_860079505", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R51": { "role": "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesParentheticalsDetails", "longName": "996350 - Disclosure - Financial Instruments and Risk Management - Schedule of Foreign Currency Against the Functional Currencies (Parentheticals) (Details)", "shortName": "Financial Instruments and Risk Management - Schedule of Foreign Currency Against the Functional Currencies (Parentheticals) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "cref_1638724649", "name": "cmnd:ImpactOfAStrengtheningOrWeakeningOfForeignExchangeRate", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_1638724649", "name": "cmnd:ImpactOfAStrengtheningOrWeakeningOfForeignExchangeRate", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R52": { "role": "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails", "longName": "996351 - Disclosure - Financial Instruments and Risk Management - Schedule of Contractual Maturities of Financial Liabilities (Details)", "shortName": "Financial Instruments and Risk Management - Schedule of Contractual Maturities of Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "cref_817131922", "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_817131922", "name": "ifrs-full:LeaseLiabilities", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R53": { "role": "http://clearmindmedicine.com/20260731/role/SegmentedInformationDetails", "longName": "996352 - Disclosure - Segmented Information (Details)", "shortName": "Segmented Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "cref_55821411", "name": "cmnd:NumberOfOperatingSegment", "unitRef": "uref_622090509", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "cref_55821411", "name": "cmnd:NumberOfOperatingSegment", "unitRef": "uref_622090509", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true, "unique": true } }, "R54": { "role": "http://clearmindmedicine.com/20260731/role/CommitmentsDetails", "longName": "996353 - Disclosure - Commitments (Details)", "shortName": "Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "cref_817131922", "name": "cmnd:AreaOfLandUsedForOffice", "unitRef": "uref_817131922", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_368246629", "name": "cmnd:AreaOfLandUsedForOffice", "unitRef": "uref_817131922", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } }, "R55": { "role": "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails", "longName": "996354 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "cref_817131922", "name": "cmnd:AggregatePurchasePrice", "unitRef": "uref_1717180837", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDebtSecuritiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "cref_1264397625", "name": "cmnd:PercentageOfInterestRate", "unitRef": "uref_1264397625", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ea030403301ex99-1.htm", "unique": true } } }, "tag": { "cmnd_AccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "AccruedInterest", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Accrued Interest", "documentation": "The amount of accrued interest." } } }, "auth_ref": [] }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated other comprehensive income" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated other comprehensive income [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r221" ] }, "cmnd_AcquisitionOfShorttermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "AcquisitionOfShorttermInvestment", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of short-term investment (Note 3)", "label": "Acquisition Of Shortterm Investment", "documentation": "Amount of acquisition of short-term investment." } } }, "auth_ref": [] }, "cmnd_AdditionstoShorttermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "AdditionstoShorttermInvestment", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additionsto Shortterm Investment", "documentation": "Amount of additions to short term investment." } } }, "auth_ref": [] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding for the purposes of diluted loss per share", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r22" ] }, "ifrs-full_AdjustmentsForAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForAmortisationExpense", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Adjustments for amortisation expense" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssetsAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for:", "label": "Adjustments for decrease (increase) in accrued income including contract assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInFinancialAssetsHeldForTrading": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInFinancialAssetsHeldForTrading", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value of short-term investments", "label": "Adjustments for decrease (increase) in financial assets held for trading" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in financial assets held for trading to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Financial assets; Financial assets at fair value through profit or loss, classified as held for trading; Profit (loss)]" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in prepaid expenses", "label": "Adjustments for decrease (increase) in prepaid expenses" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "(Increase) decrease in other receivables", "label": "Adjustments for decrease (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Changes in fair value of derivative warrant liabilities", "label": "Adjustments for gains (losses) on change in fair value of derivatives" } }, "en": { "role": { "documentation": "Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in accounts payable and accrued liabilities", "label": "Adjustments for increase (decrease) in trade accounts payable" } } }, "auth_ref": [ "r212" ] }, "cmnd_AdjustmentsForIncreasedecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "AdjustmentsForIncreasedecreaseInDueToRelatedParties", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in amounts due to / from related parties", "label": "Adjustments For Increasedecrease In Due To Related Parties", "documentation": "Adjustments for the increase (decrease) in due to related parties." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForInterestExpense", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liability", "label": "Adjustments for interest expense" } } }, "auth_ref": [ "r214" ] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Adjustments for share-based payments" } } }, "auth_ref": [ "r213" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange rate differences", "label": "Adjustments for unrealised foreign exchange losses (gains)" } } }, "auth_ref": [ "r183", "r213" ] }, "cmnd_AggregatePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "AggregatePrincipalAmount", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal amount", "label": "Aggregate Principal Amount", "documentation": "The amount of aggregate principal amount." } } }, "auth_ref": [] }, "cmnd_AggregatePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "AggregatePurchasePrice", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchase price", "terseLabel": "Aggregate purchase price", "label": "Aggregate Purchase Price", "documentation": "The amount of aggregate purchase price." } } }, "auth_ref": [] }, "cmnd_AllocatedShareAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "AllocatedShareAmount", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Allocated share amount", "documentation": "The allocated share amount." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "cmnd_April2023Member": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "April2023Member", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Warrants [Member]", "label": "April 2023 [Member]" } } }, "auth_ref": [] }, "cmnd_April2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "April2023WarrantsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Warrants [Member]", "label": "April2023 Warrants Member" } } }, "auth_ref": [] }, "cmnd_AreaOfLandUsedForOffice": { "xbrltype": "areaItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "AreaOfLandUsedForOffice", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Area of land used for office space (in Square Meters)", "label": "Area Of Land Used For Office", "documentation": "Area of land used for office." } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r50", "r51", "r54", "r97", "r99", "r147", "r148", "r162" ] }, "cmnd_BIRADLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "BIRADLicenseAgreementMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BIRAD License Agreement [Member]", "label": "BIRADLicense Agreement Member" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share, basic", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r20", "r21" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of Range [Member]", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r34", "r56", "r67", "r76", "r118", "r187", "r188", "r218" ] }, "cmnd_CLAInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CLAInvestorsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CLA Investors [Member]", "label": "CLAInvestors Member" } } }, "auth_ref": [] }, "ifrs-full_CapitalCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalCommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Commitments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails": { "parentTag": "cmnd_ForeignCurrencyFinancialAssetsAndLiabilities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited", "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and cash equivalents at end of period", "negatedLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r35", "r48", "r119", "r161" ] }, "cmnd_CashFlowsFromUsedInDecreaseIncreaseInExerciseOfWarrantsOfShortTermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CashFlowsFromUsedInDecreaseIncreaseInExerciseOfWarrantsOfShortTermInvestment", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants held as short-term investment (Note 3)", "label": "Cash Flows From Used in Decrease Increase in Exercise of Warrants of Short-Term Investment", "documentation": "The amount of cash flows from used in decrease increase in exercise of warrants of short-term investment." } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in restricted cash", "label": "Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } } }, "auth_ref": [ "r210" ] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of short-term investments (Note 3)", "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r210" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash generated from financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r30", "r36" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r30", "r36" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r30", "r36" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperations", "presentation": [ "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow from operations", "label": "Cash flows from (used in) operations" } }, "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } } }, "auth_ref": [ "r182", "r183" ] }, "cmnd_CashReceivedAsInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CashReceivedAsInterest", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received as interest", "label": "Cash Received As Interest", "documentation": "Represent the amount of cash received as interest." } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsDetails", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofBalanceswithRelatedPartiesDetails", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails", "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/StockOptionsDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r14", "r129" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsDetails", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofBalanceswithRelatedPartiesDetails", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails", "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/StockOptionsDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r14", "r129" ] }, "cmnd_ChangesInFairValueOfConvertibleLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ChangesInFairValueOfConvertibleLoans", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value of convertible loans (Note 6)", "label": "Changes in Fair Value of Convertible Loans", "documentation": "The amount of changes in fair value of convertible loans." } } }, "auth_ref": [] }, "cmnd_ChangesInFairValueOfShorttermInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ChangesInFairValueOfShorttermInvestment", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value", "label": "Changes In Fair Value Of Shortterm Investment", "documentation": "The amount of changes in fair value of short-term investments." } } }, "auth_ref": [] }, "cmnd_ChangesInFairValueOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ChangesInFairValueOfShorttermInvestments", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Changes in fair value of short-term investments (Note 3)", "label": "Changes In Fair Value Of Shortterm Investments", "documentation": "The amount is changes in fair value of short-term investments." } } }, "auth_ref": [] }, "cmnd_ChargingRoboticsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ChargingRoboticsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Charging Robotics [Member]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfCashPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfCashPaymentsAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in working capital:", "label": "Classes of cash payments from operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r88", "r89", "r91", "r92", "r143", "r145" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r88", "r89", "r91", "r92", "r143", "r145" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5", "r124" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r5", "r124" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r116", "r152", "r171" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r116", "r152", "r171" ] }, "cmnd_CommitmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CommitmentsDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Commitments (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_CommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CommitmentsLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "label": "Commitments [Line Items]" } } }, "auth_ref": [] }, "cmnd_CommonPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CommonPerShare", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common share for every one common share (in Dollars per share)", "label": "Common Per Share", "documentation": "The number of common per share." } } }, "auth_ref": [] }, "cmnd_CommonShareHeld": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CommonShareHeld", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnauditedParentheticals" ], "lang": { "en-us": { "role": { "label": "Common Share Held", "terseLabel": "Common share held", "documentation": "Number of common share held." } } }, "auth_ref": [] }, "cmnd_CommonSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CommonSharesMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Shares [Member]", "label": "Common Shares Member" } } }, "auth_ref": [] }, "cmnd_CommonSharesReservedForIssuancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CommonSharesReservedForIssuancePeriod", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares reserved for issuance period", "label": "Common Shares Reserved For Issuance Period", "documentation": "Common shares reserved for issuance period." } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r158" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r158" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net Loss and Comprehensive loss", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r38", "r40", "r47", "r131", "r137", "r155", "r174", "r184" ] }, "cmnd_CondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParentheticals" ], "lang": { "en-us": { "role": { "label": "Condensed Interim Consolidated Statements of Operations and Comprehensive Loss [Line Items]" } } }, "auth_ref": [] }, "cmnd_CondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CondensedInterimConsolidatedStatementsOfOperationsAndComprehensiveLossTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParentheticals" ], "lang": { "en-us": { "role": { "label": "Condensed Interim Consolidated Statements of Operations and Comprehensive Loss [Table]" } } }, "auth_ref": [] }, "cmnd_CondensedInterimStatementsOfChangesInShareholdersEquityUnauditedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "CondensedInterimStatementsOfChangesInShareholdersEquityUnauditedAbstract", "lang": { "en-us": { "role": { "label": "Condensed Interim Statements Of Changes In Shareholders Equity Unaudited Abstract" } } }, "auth_ref": [] }, "cmnd_ConsultantsDirectorsAndOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ConsultantsDirectorsAndOfficersMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consultants Directors and Officers [Member]", "label": "Consultants Directors And Officers Member" } } }, "auth_ref": [] }, "cmnd_ConversionOfCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ConversionOfCommonShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of common shares (in Shares)", "label": "Conversion Of Common Shares", "documentation": "The amount of conversion of common shares." } } }, "auth_ref": [] }, "cmnd_ConversionOfPromissoryNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ConversionOfPromissoryNotes", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of aggregate amount", "label": "Conversion of Promissory Notes", "documentation": "The amount of conversion of promissory notes." } } }, "auth_ref": [] }, "cmnd_ConversionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ConversionPricePerShare", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price", "label": "Conversion Price Per Share", "documentation": "The per share of conversion price." } } }, "auth_ref": [] }, "cmnd_ConvertibleLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ConvertibleLoan", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 3.0 }, "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited", "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning", "terseLabel": "Convertible loans (Note 6)", "verboseLabel": "Convertible loans", "label": "Convertible Loan", "documentation": "The amount of convertible loans." } } }, "auth_ref": [] }, "cmnd_ConvertibleLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ConvertibleLoans", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at ending", "label": "Convertible Loans", "documentation": "The amount of convertible loans." } } }, "auth_ref": [] }, "cmnd_ConvertibleLoansDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ConvertibleLoansDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Loans (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_ConvertibleLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ConvertibleLoansMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Loans [Member]", "label": "Convertible Loans Member" } } }, "auth_ref": [] }, "cmnd_ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Loans - Schedule of Fair Value of the Promissory Notes (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_ConvertibleWarrantCommonShares": { "xbrltype": "perShareItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ConvertibleWarrantCommonShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of shares (in Dollars per share)", "label": "Convertible Warrant Common Shares", "documentation": "Amount of convertible warrant common shares." } } }, "auth_ref": [] }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 0.0 }, "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails": { "parentTag": "cmnd_ForeignCurrencyFinancialAssetsAndLiabilities", "weight": 1.0, "order": 1.0 }, "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Current accrued expenses and other current liabilities" } }, "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r43", "r165", "r184" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Current derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r224" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentInvestments", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning shares", "periodEndLabel": "Ending shares", "terseLabel": "Short-term investments (Note 3)", "label": "Current investments" } }, "en": { "role": { "documentation": "The amount of current investments." } } }, "auth_ref": [ "r224" ] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term portion of lease liabilities (Note 14e)", "label": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r59" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r45", "r166", "r184" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r222" ] }, "ifrs-full_CurrentRestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentRestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Current restricted cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_CurrentWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentWarrantLiability", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Derivative warrant liabilities", "terseLabel": "Derivative warrant liabilities (Note 5)", "label": "Current warrant liability" } }, "en": { "role": { "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_DebtInstrumentsHeldAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DebtInstrumentsHeldAbstract", "lang": { "en-us": { "role": { "label": "Short-Term Investments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DebtSecurities", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Convertible loans", "label": "Debt instruments issued" } }, "en": { "role": { "documentation": "The amount of instruments issued by the entity that represent indebtedness." } } }, "auth_ref": [ "r224" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use asset", "label": "Depreciation, right-of-use assets" } } }, "auth_ref": [ "r60", "r104" ] }, "cmnd_DerivativeWarrantLiabilitiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DerivativeWarrantLiabilitiesDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Warrant Liabilities [Table]", "label": "Derivative Warrant Liabilities (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Warrant Liabilities - Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Table]", "label": "Derivative Warrant Liabilities - Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Warrant Liabilities - Schedule of Changes in the Derivative Warrant Liability [Table]", "label": "Derivative Warrant Liabilities - Schedule of Changes in the Derivative Warrant Liability (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_DescriptionOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DescriptionOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/AccountingPoliciesbyPolicyPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Estimates and Judgments", "label": "Description Of Accounting Policy For Accounting Judgements And Estimates Explanatory", "documentation": "Represent the description of accounting policy for accounting judgements and estimates." } } }, "auth_ref": [] }, "cmnd_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/AccountingPoliciesbyPolicyPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Description Of Accounting Policy For Basis Of Presentation Explanatory", "documentation": "Represent the description of accounting policy for basis of presentation." } } }, "auth_ref": [] }, "cmnd_DescriptionOfAccountingPolicyForCondensedInterimConsolidatedFinancialInformation": { "xbrltype": "textBlockItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DescriptionOfAccountingPolicyForCondensedInterimConsolidatedFinancialInformation", "presentation": [ "http://clearmindmedicine.com/20260731/role/AccountingPoliciesbyPolicyPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Condensed Interim Consolidated Financial Information", "label": "Description Of Accounting Policy For Condensed Interim Consolidated Financial Information", "documentation": "Description of accounting policy for condensed interim consolidated financial information." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Expected volatility, share options granted" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life (in Years)", "label": "Option life, share options granted" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Risk free interest rate, share options granted" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r77" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share, diluted", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r20", "r21" ] }, "cmnd_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DirectorsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofBalanceswithRelatedPartiesDetails", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amounts owed to directors [Member]", "terseLabel": "Directors [Member]", "label": "Directors Member" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Compensation to Key Management Personnel for Services [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionAbstract", "lang": { "en-us": { "role": { "label": "Nature of Operations and Going Concern [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Nature of Operations and Going Concern [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/MaterialAccountingPolicyInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Material Accounting Policy Information", "label": "Disclosure of changes in accounting policies [text block]" } }, "en": { "role": { "documentation": "The disclosure of changes made to accounting policies by the entity." } } }, "auth_ref": [ "r219" ] }, "cmnd_DisclosureOfChangesInWarrantsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DisclosureOfChangesInWarrantsExplanatoryTextBlock", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Warrants", "label": "Disclosure Of Changes In Warrants Explanatory Text Block", "documentation": "Tabular disclosure of changes in warrants." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Share Capital [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails", "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Capital [Line Items]", "label": "Schedule of RSUs [Line Items]", "verboseLabel": "Restricted Share Units [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/Commitments" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments", "label": "Disclosure of commitments and contingent liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_DisclosureOfDebtSecuritiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDebtSecuritiesExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoans" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loans", "label": "Disclosure of debt instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative warrant liabilities", "label": "Disclosure of derivative financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Loans [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Foreign Currency Against the Functional Currencies", "label": "Disclosure of effect of changes in foreign exchange rates [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r9" ] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/SegmentedInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segmented Information", "label": "Disclosure of entity's operating segments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r101" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Disclosure of events after reporting period [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r1" ] }, "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of the Promissory Notes", "label": "Disclosure of fair value measurement [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for fair value measurement." } } }, "auth_ref": [ "r55" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfEquityLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of the Promissory Notes [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Assets and Liabilities Measured at Fair Value [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value", "label": "Disclosure of fair value of financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfPlanAssetsLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Investments [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Financial Instruments and Risk Management [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in the Derivative Warrant Liability", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities [Line Items]", "terseLabel": "Financial Instruments and Risk Management [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Changes in the Derivative Warrant Liability [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/CapitalManagement" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Management", "label": "Disclosure of financial risk management [text block]" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r219" ] }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGoingConcernExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcern" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of Operations and Going Concern", "label": "Disclosure of going concern [text block]" } }, "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } } }, "auth_ref": [ "r219" ] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Compensation to Key Management Personnel for Services", "label": "Disclosure of information about key management personnel [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Disclosure of investments accounted for using equity method [text block]" } }, "en": { "role": { "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagement" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments and Risk Management", "label": "Disclosure of nature and extent of risks arising from financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of information that enables users of financial statements to evaluate the nature and extent of risks arising from financial instruments to which the entity is exposed. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r84" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Contractual Maturities of Financial Liabilities [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract", "lang": { "en-us": { "role": { "label": "Capital Management [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Segmented Information [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants Outstanding", "label": "Disclosure of range of exercise prices of outstanding share options [text block]" } }, "en": { "role": { "documentation": "The disclosure of the range of exercise prices for outstanding share options." } } }, "auth_ref": [ "r76" ] }, "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofChangesinWarrantsDetails", "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of range of exercise prices of outstanding share options [line items]", "terseLabel": "Schedule of Warrants Outstanding [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r15" ] }, "cmnd_DisclosureOfRestrictedShareUnitsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DisclosureOfRestrictedShareUnitsTextBlock", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnits" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Units", "label": "Disclosure Of Restricted Share Units Text Block", "documentation": "The entire disclosure for restricted share units." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRisksToWhichEntityIsExposedWhenCurrencyIsNotExchangeableLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRisksToWhichEntityIsExposedWhenCurrencyIsNotExchangeableLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesParentheticalsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Foreign Currency Against the Functional Currencies [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapital" ], "lang": { "en-us": { "role": { "terseLabel": "Share Capital", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r117", "r153", "r172" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptions" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Disclosure of share-based payment arrangements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r73" ] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability", "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities." } } }, "auth_ref": [ "r52" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Stock Options [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Balances with Related Parties", "label": "Disclosure of transactions between related parties [text block]" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r13", "r128" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsDetails", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Balances with Related Parties [Line Items]", "terseLabel": "Related Party Transactions [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of voluntary change in accounting policy [abstract]" } } }, "auth_ref": [] }, "cmnd_DisclosureOfWarrantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DisclosureOfWarrantsTextBlock", "presentation": [ "http://clearmindmedicine.com/20260731/role/Warrants" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Disclosure Of Warrants Text Block", "documentation": "The entire disclosure of warrants." } } }, "auth_ref": [] }, "cmnd_DisclosureofFairValueofCommonSharesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DisclosureofFairValueofCommonSharesExplanatory", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-Term Investments", "label": "Disclosureof Fair Valueof Common Shares Explanatory", "documentation": "Tabular disclosure of fair value of common shares." } } }, "auth_ref": [] }, "ifrs-full_DiscountRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DiscountRateMeasurementInputMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield [Member]", "label": "Discount rate, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation." } } }, "auth_ref": [ "r216" ] }, "cmnd_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "DocumentAndEntityInformationAbstract", "lang": { "en-us": { "role": { "label": "" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rate changes on cash and cash equivalents", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r31", "r32" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r207" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incorporated date", "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://clearmindmedicine.com/20260731/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r207" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited", "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance", "periodEndLabel": "Balance", "totalLabel": "Total shareholders\u2019 equity", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r37", "r39", "r50", "r51", "r54", "r130", "r136", "r147", "r148", "r154", "r162", "r167" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r162" ] }, "cmnd_ExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ExercisePriceMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price\t[Member]", "label": "Exercise Price Member" } } }, "auth_ref": [] }, "cmnd_ExercisePriceOfCommonShares": { "xbrltype": "perShareItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ExercisePriceOfCommonShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of common shares", "label": "Exercise Price Of Common Shares", "documentation": "Represent the exercise price of common shares." } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceOfOutstandingShareOptions2019", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per warrant shares (in Dollars per share and Dollars per share)", "verboseLabel": "Exercise price (in Dollars per share)", "netLabel": "Warrants exercise price (in Dollars per share)", "label": "Exercise price of outstanding share options" } }, "en": { "role": { "documentation": "The exercise price of outstanding share options." } } }, "auth_ref": [ "r76" ] }, "cmnd_ExercisePriceOfPerCommonPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ExercisePriceOfPerCommonPerShare", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per common share (in Dollars per share)", "label": "Exercise Price Of Per Common Per Share", "documentation": "exercise price of per common per share." } } }, "auth_ref": [] }, "cmnd_ExercisePriceOfWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ExercisePriceOfWarrants", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of warrants", "label": "Exercise Price of Warrants", "documentation": "The amount of exercise price of warrants." } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price", "label": "Exercise price, share options granted" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense (in Dollars)", "label": "Expense from share-based payment transactions" } } }, "auth_ref": [ "r79", "r140" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsAbstract", "lang": { "en-us": { "role": { "label": "Stock Options [Abstract]" } } }, "auth_ref": [] }, "cmnd_ExpiryDateApril52028Member": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ExpiryDateApril52028Member", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 5, 2028 [Member]", "label": "Expiry Date April52028 Member" } } }, "auth_ref": [] }, "cmnd_ExpiryDateJanuary152029Member": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ExpiryDateJanuary152029Member", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 15, 2029 [Member]", "label": "Expiry Date January152029 Member" } } }, "auth_ref": [] }, "cmnd_ExpiryDateNovember172027Member": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ExpiryDateNovember172027Member", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "November 17, 2027 [Member]", "label": "Expiry Date November172027 Member" } } }, "auth_ref": [] }, "cmnd_ExpiryDateSeptember172028Member": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ExpiryDateSeptember172028Member", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "September 17, 2028 [Member]", "label": "Expiry Date September172028 Member" } } }, "auth_ref": [] }, "cmnd_FairValueOfRSU": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "FairValueOfRSU", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value (in Dollars)", "label": "Fair Value Of RSU", "documentation": "Represent the amount of fair value of RSU." } } }, "auth_ref": [] }, "cmnd_FairValueOfSharesForConsultingServices": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "FairValueOfSharesForConsultingServices", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of shares for consulting services (in Dollars)", "label": "Fair Value Of Shares For Consulting Services", "documentation": "Fair value of shares for consulting services." } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance expenses", "verboseLabel": "Finance expense", "label": "Finance costs" } } }, "auth_ref": [ "r175" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total finance income", "label": "Finance income (cost)" } } }, "auth_ref": [ "r228" ] }, "cmnd_FinancialInstrumentsandRiskManagementDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "FinancialInstrumentsandRiskManagementDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments and Risk Management (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments and Risk Management - Schedule of Assets and Liabilities Measured at Fair Value (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments and Risk Management - Schedule of Contractual Maturities of Financial Liabilities (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments and Risk Management - Schedule of Foreign Currency Against the Functional Currencies (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesParentheticalsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesParentheticalsDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesParentheticalsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments and Risk Management - Schedule of Foreign Currency Against the Functional Currencies (Parentheticals) (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r83" ] }, "cmnd_FirstAndSecondInitialPromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "FirstAndSecondInitialPromissoryNotesMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First and Second Initial Promissory Notes [Member]", "label": "First And Second Initial Promissory Notes Member" } } }, "auth_ref": [] }, "cmnd_FloorPrice": { "xbrltype": "perShareItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "FloorPrice", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Floor price (in Dollars per share)", "label": "Floor Price", "documentation": "Floor price." } } }, "auth_ref": [] }, "cmnd_ForeignCurrencyFinancialAssetsAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ForeignCurrencyFinancialAssetsAndLiabilities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total foreign currency financial assets and liabilities", "label": "Foreign Currency Financial Assets And Liabilities", "documentation": "The amount of foreign currency financial assets and liabilities." } } }, "auth_ref": [] }, "cmnd_ForeignCurrencyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ForeignCurrencyPercentage", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency, percentage", "label": "Foreign Currency Percentage", "documentation": "Percentage of foreign currency." } } }, "auth_ref": [] }, "cmnd_ForeignExchangeRateRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ForeignExchangeRateRiskMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesParentheticalsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Rate Risk [Member]", "label": "Foreign Exchange Rate Risk Member" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of warrants", "terseLabel": "Changes in fair value of derivative warrant liabilities (Note 5)", "definitionGuidance": "Gain on revaluation of total derivative warrant liabilities", "label": "Gains (losses) on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r228" ] }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivativesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnChangeInFairValueOfDerivativesAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Finance income (expenses)", "label": "Gains (losses) on change in fair value of derivatives [abstract]" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange gain (loss)", "label": "Foreign exchange gain (loss)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r7", "r125", "r159" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and administrative expenses, operating" } } }, "auth_ref": [ "r222" ] }, "cmnd_GrossProceedsOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "GrossProceedsOfWarrants", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds (in Dollars)", "label": "Gross Proceeds Of Warrants", "documentation": "The amount of warrants gross proceeds." } } }, "auth_ref": [] }, "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "HistoricalVolatilityForSharesMeasurementInputMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility [Member]", "label": "Historical volatility for shares, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for the historical volatility for shares used as a measurement input." } } }, "auth_ref": [ "r186" ] }, "cmnd_ImpactOfAStrengtheningOrWeakeningOfForeignExchangeRate": { "xbrltype": "percentItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ImpactOfAStrengtheningOrWeakeningOfForeignExchangeRate", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesParentheticalsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of a strengthening or weakening of foreign exchange rate", "label": "Impact Of AStrengthening Or Weakening Of Foreign Exchange Rate", "documentation": "The percentage amount of Impact of a strengthening or weakening of foreign exchange rate." } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax expenses", "label": "Income tax expense (income), income taxes" } } }, "auth_ref": [ "r2", "r3", "r4", "r17", "r49", "r96", "r121", "r122", "r123", "r176" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r35", "r119" ] }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation (in Shares)", "label": "Increase (decrease) in number of ordinary shares issued" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r222" ] }, "cmnd_IncreaseDecreaseInSharesExerciseOfWarrant": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "IncreaseDecreaseInSharesExerciseOfWarrant", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants (in Shares)", "label": "Increase Decrease In Shares Exercise Of Warrant", "documentation": "The number of warrant exercise shares." } } }, "auth_ref": [] }, "cmnd_IncreaseDecreaseIssuanceOfSharesOnPrefundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "IncreaseDecreaseIssuanceOfSharesOnPrefundedWarrants", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of prefunded warrants", "label": "Increase Decrease Issuance of Shares on Prefunded Warrants", "documentation": "The amount of issuance of shares on prefunded warrants." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares upon conversion of convertible loans (Notes 6, 7c(viii))", "label": "Increase (decrease) through conversion of convertible instruments, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } } }, "auth_ref": [ "r220" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants", "label": "Increase (decrease) through exercise of warrants, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r220" ] }, "cmnd_IncreaseDecreaseThroughIssuanceOfCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "IncreaseDecreaseThroughIssuanceOfCommonShares", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares", "label": "Increase Decrease Through Issuance Of Common Shares", "documentation": "The amount from issuance of common shares." } } }, "auth_ref": [] }, "cmnd_IncreaseDecreaseThroughIssuanceOfSharesOnPrefundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "IncreaseDecreaseThroughIssuanceOfSharesOnPrefundedWarrants", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares on prefunded warrants (in Shares)", "label": "Increase Decrease Through Issuance of Shares on Prefunded Warrants", "documentation": "Number of issuance of shares on prefunded warrants." } } }, "auth_ref": [] }, "cmnd_IncreaseDecreaseThroughIssuanceofCommonSharesUponVestingofRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "IncreaseDecreaseThroughIssuanceofCommonSharesUponVestingofRestrictedStockUnits", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon vesting of restricted share units", "label": "Increase Decrease Through Issuanceof Common Shares Upon Vestingof Restricted Stock Units", "documentation": "The increase (decrease) in equity resulting from the issuance of common shares upon vesting of restricted stock units." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r157" ] }, "cmnd_IncreaseDecreaseinNumberofSharesConversionOfConvertibleLoansNotes": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "IncreaseDecreaseinNumberofSharesConversionOfConvertibleLoansNotes", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares upon conversion of convertible loans (Notes 6, 7c(viii)) (in Shares)", "label": "Increase Decreasein Numberof Shares Conversion Of Convertible Loans Notes", "documentation": "The number of conversion shares." } } }, "auth_ref": [] }, "cmnd_IncreaseDecreseIssuanceOfCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "IncreaseDecreseIssuanceOfCommonShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares (in Shares)", "label": "Increase Decrese Issuance Of Common Shares", "documentation": "Issuance of common shares." } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r26", "r133", "r160" ] }, "ifrs-full_InterestExpenseOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnBorrowings", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on convertible loans", "label": "Interest expense on borrowings" } } }, "auth_ref": [ "r222" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid as interest on lease liability", "label": "Interest expense on lease liabilities, financing" } } }, "auth_ref": [ "r61", "r105" ] }, "ifrs-full_InterestIncomeOnDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeOnDeposits", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income on deposits", "label": "Interest income on deposits" } } }, "auth_ref": [ "r222" ] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid in respect of taxes", "label": "Interest paid, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_InterestRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestRateMeasurementInputMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate [Member]", "label": "Interest rate, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for an interest rate used as a measurement input." } } }, "auth_ref": [ "r185" ] }, "cmnd_Investment": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "Investment", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment (in Dollars)", "label": "Investment", "documentation": "Investment." } } }, "auth_ref": [] }, "cmnd_InvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "InvestorsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investors [Member]", "verboseLabel": "CLA Investors [Member]", "label": "Investors Member" } } }, "auth_ref": [] }, "cmnd_IssuanceOfCommonShareFromUponVestingOfRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "IssuanceOfCommonShareFromUponVestingOfRestrictedStockUnits", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon vesting of restricted share units (in Shares)", "label": "Issuance Of Common Share From Upon Vesting Of Restricted Stock Units", "documentation": "Issuance of common shares from upon vesting of restricted stock units." } } }, "auth_ref": [] }, "cmnd_IssuanceOfSharesUponConversionOfConvertibleLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "IssuanceOfSharesUponConversionOfConvertibleLoans", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares upon conversion of convertible loans (Notes 6,7c (viii))", "label": "Issuance Of Shares Upon Conversion Of Convertible Loans", "documentation": "Represent the amount of issuance of shares upon conversion of convertible loans." } } }, "auth_ref": [] }, "cmnd_IssuePrefundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "IssuePrefundedWarrants", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issue pre-funded warrants", "label": "Issue Prefunded Warrants", "documentation": "Number of issues of pre-funded warrants." } } }, "auth_ref": [] }, "ifrs-full_IssuesFairValueMeasurementAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuesFairValueMeasurementAssets", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Issues, fair value measurement, assets" } }, "en": { "role": { "documentation": "The increase in the fair value measurement of assets resulting from issues of those assets. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r53" ] }, "cmnd_January2024WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "January2024WarrantsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2024 Warrants [Member]", "label": "January2024 Warrants Member" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Key management personnel compensation", "label": "Key management personnel compensation, operating" } } }, "auth_ref": [ "r12", "r127" ] }, "cmnd_KeyManagementPersonnelCompensationConsultingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "KeyManagementPersonnelCompensationConsultingFees", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consulting fees", "label": "Key Management Personnel Compensation Consulting Fees", "documentation": "The amount of compensation to key management personnel in the form of consulting fees." } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 25.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Directors\u2019 fees", "label": "Key management personnel compensation, other long-term employee benefits, operating" } } }, "auth_ref": [ "r10" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation", "label": "Key management personnel compensation, share-based payment" } } }, "auth_ref": [ "r11" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Within 2-5 years [Member]", "label": "Later than one year and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than five years." } } }, "auth_ref": [ "r108", "r111", "r192", "r195" ] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r59" ] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted prices in active markets for identical instruments (Level 1) [Member]", "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r6", "r24", "r25", "r51", "r132", "r148" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant other observable inputs (Level 2) [Member]", "label": "Level 2 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r24", "r25", "r51", "r132", "r148" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs (Level 3) [Member]", "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r24", "r25", "r51", "r132", "r148" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6", "r51", "r148" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r6", "r51", "r148" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r50", "r51", "r54", "r97", "r100", "r147", "r148", "r162" ] }, "ifrs-full_LifetimeExpectedCreditLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LifetimeExpectedCreditLossesMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life [Member]", "label": "Lifetime expected credit losses [member]" } }, "en": { "role": { "documentation": "This member stands for the expected credit losses that result from all possible default events over the expected life of a financial instrument. [Refer: Type of measurement of expected credit losses [domain]]" } } }, "auth_ref": [ "r87", "r90", "r142", "r144" ] }, "ifrs-full_LoansAndAdvancesAtAmortisedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LoansAndAdvancesAtAmortisedCostAbstract", "lang": { "en-us": { "role": { "label": "Convertible Loans [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_LossesOnDisposalsOfInvestmentProperties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LossesOnDisposalsOfInvestmentProperties", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposals", "label": "Losses on disposals of investment properties, operating" } } }, "auth_ref": [ "r222" ] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contractual Maturities of Financial Liabilities", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r93", "r146" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r57", "r63", "r64", "r65", "r66", "r67", "r72", "r82", "r94", "r102", "r103", "r109", "r112", "r141", "r164", "r178", "r193" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r57", "r63", "r64", "r65", "r66", "r67", "r72", "r82", "r102", "r103", "r109", "r112", "r141", "r164", "r178", "r193", "r194" ] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r28", "r29", "r50", "r135", "r147" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r28", "r29", "r50", "r135", "r147" ] }, "cmnd_NatureofOperationsandGoingConcernDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NatureofOperationsandGoingConcernDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Nature of Operations and Going Concern (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_NetForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetForeignExchangeLoss", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Impact of a 10% strengthening or weakening of foreign exchange rate", "label": "Net foreign exchange loss" } } }, "auth_ref": [ "r208", "r223" ] }, "cmnd_NetProceedFromOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NetProceedFromOffering", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate gross proceeds (in Dollars)", "label": "Net Proceed From Offering", "documentation": "The amount of net proceeds from offering." } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r120" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r120" ] }, "cmnd_NonadjustingEventsAfterReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NonadjustingEventsAfterReportingPeriodMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-adjusting Events After Reporting Period [Member]", "label": "Nonadjusting Events After Reporting Period Member" } } }, "auth_ref": [] }, "cmnd_NoncashFinancingAndInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NoncashFinancingAndInvestingActivitiesAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash financing and investing activities", "label": "Noncash Financing And Investing Activities Abstract" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r44", "r165", "r184" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term lease liabilities", "label": "Non-current lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r59" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r46", "r166", "r184" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Within 1 year [Member]", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r63", "r64", "r72", "r107", "r110", "r163", "r193", "r195" ] }, "ifrs-full_NotesAndDebenturesIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotesAndDebenturesIssued", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory notes aggregate principal amount", "label": "Notes and debentures issued" } }, "en": { "role": { "documentation": "The amount of notes and debentures issued by the entity." } } }, "auth_ref": [ "r222" ] }, "cmnd_NumberOfAbeyanceSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NumberOfAbeyanceSharesIssued", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Number of abeyance shares issued", "documentation": "Shares held in abeyance are shares issued." } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of RSUs, Granted", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r78", "r217" ] }, "cmnd_NumberOfOperatingSegment": { "xbrltype": "integerItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NumberOfOperatingSegment", "presentation": [ "http://clearmindmedicine.com/20260731/role/SegmentedInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segment", "label": "Number Of Operating Segment", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails", "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofChangesinWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of RSUs, Exercised", "negatedLabel": "Number of warrants, Exercise of warrants", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r217" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofChangesinWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of warrants, Expiration of warrants", "label": "Number of other equity instruments expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement." } } }, "auth_ref": [ "r217" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofChangesinWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of warrants, Balance beginning", "periodEndLabel": "Number of warrants, Balance ending", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r217" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r74", "r75", "r76", "r138", "r139" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails", "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails", "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares issued", "netLabel": "Restricted share units issued (in Shares)", "terseLabel": "Shares issued", "periodEndLabel": "Number of RSUs, Ending Balance", "periodStartLabel": "Number of RSUs, Beginning balance", "label": "Common shares issued (in Shares)" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r220" ] }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssuedAndFullyPaid", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares issued of RSU\u2019s fully vested", "label": "Number of shares issued and fully paid" } }, "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } } }, "auth_ref": [ "r113", "r149", "r168" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)", "label": "Number of shares outstanding at beginning of period" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r115", "r151", "r170" ] }, "cmnd_NumberOfSharesReceivedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NumberOfSharesReceivedInTransaction", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares received in transaction", "label": "Number Of Shares Received In Transaction", "documentation": "The number of shares received in transaction." } } }, "auth_ref": [] }, "cmnd_NumberOfSharesToBeIssuedFromTheExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NumberOfSharesToBeIssuedFromTheExerciseOfWarrants", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares to be issued from the exercise of warrants (warrant shares)", "label": "Number Of Shares To Be Issued From The Exercise Of Warrants", "documentation": "Number of number of shares to be issued from the exercise of warrants." } } }, "auth_ref": [] }, "cmnd_NumberOfThirdParties": { "xbrltype": "integerItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NumberOfThirdParties", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third parties", "label": "Number Of Third Parties", "documentation": "The number of third parties." } } }, "auth_ref": [] }, "cmnd_NumberOfWarrantOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NumberOfWarrantOutstanding", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants outstanding", "label": "Number Of Warrant Outstanding", "documentation": "Number of warrants outstanding." } } }, "auth_ref": [] }, "cmnd_NumberOfWarrantShares": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NumberOfWarrantShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares", "label": "Number Of Warrant Shares", "documentation": "Number of warrants shares." } } }, "auth_ref": [] }, "cmnd_NumberOfWarrantsNumberOfSharesToBeIssuedFromTheExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NumberOfWarrantsNumberOfSharesToBeIssuedFromTheExerciseOfWarrants", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofChangesinWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants, Number of shares to be issued from the exercise of these warrants (in Shares)", "label": "Number Of Warrants Number Of Shares To Be Issued From The Exercise Of Warrants", "documentation": "Number of shares to be issued from the exercise of warrants." } } }, "auth_ref": [] }, "cmnd_NumberofCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NumberofCommonShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares", "netLabel": "Number of common shares", "verboseLabel": "Number of common shares (in Shares)", "label": "Numberof Common Shares", "documentation": "Number of common share received ." } } }, "auth_ref": [] }, "cmnd_NumberofWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "NumberofWarrantsExercised", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercised", "label": "Numberof Warrants Exercised", "documentation": "Number of warrants exercised shares." } } }, "auth_ref": [] }, "cmnd_OfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "OfficersMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofBalanceswithRelatedPartiesDetails", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amounts owed to officers [Member]", "terseLabel": "Officers [Member]", "label": "Officers Member" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating expense, operating" } } }, "auth_ref": [ "r228" ] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common share [Member]", "definitionGuidance": "Common share", "netLabel": "Common Shares [Member]", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r227" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other current receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r199", "r204" ] }, "ifrs-full_OtherExpenseByFunction": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherExpenseByFunction", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other finance expenses", "label": "Other expense, by function" } } }, "auth_ref": [ "r16", "r177", "r202" ] }, "ifrs-full_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails": { "parentTag": "cmnd_ForeignCurrencyFinancialAssetsAndLiabilities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other receivables", "label": "Other receivables" } }, "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r199", "r204" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares received per share", "verboseLabel": "Par value (in Dollars per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r114", "r150", "r169" ] }, "cmnd_PaymentOfPurchasedAdditionalTaurusShares": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PaymentOfPurchasedAdditionalTaurusShares", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of purchased additional taurus shares (in Dollars)", "label": "Payment Of Purchased Additional Taurus Shares", "documentation": "The amount of payment of purchased additional taurus shares." } } }, "auth_ref": [] }, "cmnd_PaymentsOfExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PaymentsOfExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of exercise of warrants", "label": "Payments of Exercise of Warrants", "documentation": "The amount of payments of exercise of warrants." } } }, "auth_ref": [] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of lease liabilities", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r181" ] }, "cmnd_PercentageOfInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PercentageOfInterestRate", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of interest rate", "label": "Percentage of Interest Rate", "documentation": "The percentage of interest rate." } } }, "auth_ref": [] }, "cmnd_PercentageOfIssuedAndOutstandingCommonShares": { "xbrltype": "percentItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PercentageOfIssuedAndOutstandingCommonShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of issued and outstanding common shares", "label": "Percentage Of Issued And Outstanding Common Shares", "documentation": "Percentage of issued and outstanding common shares." } } }, "auth_ref": [] }, "cmnd_PercentageOfIssuedAndOutstandingCommonSharesInTotal": { "xbrltype": "percentItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PercentageOfIssuedAndOutstandingCommonSharesInTotal", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued and outstanding common shares in total", "label": "Percentage Of Issued And Outstanding Common Shares In Total", "documentation": "Percentage of issued and outstanding common shares in total." } } }, "auth_ref": [] }, "cmnd_PercentageOfSubscriptionAmount": { "xbrltype": "percentItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PercentageOfSubscriptionAmount", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of subscription amount", "label": "Percentage Of Subscription Amount", "documentation": "The percentage of subscription amount." } } }, "auth_ref": [] }, "cmnd_PercentageOnRoyalties": { "xbrltype": "percentItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PercentageOnRoyalties", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of royalties company\u2019s net sales", "label": "Percentage On Royalties", "documentation": "Percentage on royalties." } } }, "auth_ref": [] }, "cmnd_PolyrizonLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PolyrizonLtdMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Polyrizon Ltd. [Member]", "label": "Polyrizon Ltd Member" } } }, "auth_ref": [] }, "cmnd_PolyrizonSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PolyrizonSharesMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Polyrizon shares [Member]", "label": "Polyrizon Shares Member" } } }, "auth_ref": [] }, "cmnd_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PreFundedWarrantsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrants [Member]", "label": "Pre Funded Warrants Member" } } }, "auth_ref": [] }, "cmnd_PricePerCommonShare": { "xbrltype": "perShareItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PricePerCommonShare", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per common share", "label": "Price Per Common Share", "documentation": "The price per common share." } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds received from convertible loans (Note 6)", "label": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r180" ] }, "ifrs-full_ProceedsFromCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromCurrentBorrowings", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds received from issuance of convertible loans", "label": "Proceeds from current borrowings" } }, "en": { "role": { "documentation": "The cash inflow from current borrowings obtained. [Refer: Current borrowings]" } } }, "auth_ref": [ "r211" ] }, "cmnd_ProceedsFromExerciseOfWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ProceedsFromExerciseOfWarrant", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds received from exercise of warrants (Notes 7c (ii, vii, ix))", "label": "Proceeds from Exercise of Warrant", "documentation": "Proceeds from Exercise of Warrants." } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross proceeds from warrants exercised (in Dollars)", "negatedLabel": "Exercise of warrants", "label": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r211" ] }, "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingOtherEquityInstruments", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial public offering cost (in Dollars)", "label": "Proceeds from issuing other equity instruments" } }, "en": { "role": { "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r179" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds received from issuance of shares (Note 7c (i))", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r179" ] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yissum annual maintenance fees", "label": "Professional fees expense" } } }, "auth_ref": [ "r222" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited", "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss for the period", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r38", "r40", "r97", "r98", "r131", "r137", "r156", "r173", "r184", "r190" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before taxes", "label": "Profit (loss) before tax" } } }, "auth_ref": [ "r80", "r196", "r197", "r201", "r202" ] }, "cmnd_PromissoryNotesConvertedIntoCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PromissoryNotesConvertedIntoCommonShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Converted shares", "label": "Promissory Notes Converted Into Common Shares", "documentation": "Number of shares promissory notes converted into common shares." } } }, "auth_ref": [] }, "cmnd_PromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PromissoryNotesMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory Notes [Member]", "label": "Promissory Notes Member" } } }, "auth_ref": [] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquire rate", "label": "Proportion of ownership interest in subsidiary" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r18", "r19", "r41" ] }, "ifrs-full_ProportionOfVotingRightsHeldInJointVenture": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfVotingRightsHeldInJointVenture", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of economics and rights held in joint venture", "label": "Proportion of voting rights held in joint venture" } }, "en": { "role": { "documentation": "The proportion of the voting rights in a joint venture held by the entity. [Refer: Total for all joint ventures [member]]" } } }, "auth_ref": [ "r18", "r19", "r42" ] }, "cmnd_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PublicOfferingMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Offering [Member]", "label": "Public Offering Member" } } }, "auth_ref": [] }, "cmnd_PurchasePricePerCommonShare": { "xbrltype": "perShareItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PurchasePricePerCommonShare", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price (in Dollars per share)", "label": "Purchase Price Per Common Share", "documentation": "Purchase price per common share." } } }, "auth_ref": [] }, "cmnd_PurchaseandSaleofCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PurchaseandSaleofCommonShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase and sale of common shares", "label": "Purchaseand Saleof Common Shares", "documentation": "Number of purchase and sale of common shares." } } }, "auth_ref": [] }, "cmnd_PurchasedAdditionalTaurusShares": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "PurchasedAdditionalTaurusShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional purchased taurus shares", "label": "Purchased Additional Taurus Shares", "documentation": "Number of additional taurus shares." } } }, "auth_ref": [] }, "cmnd_QXLSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "QXLSharesMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "QXL Shares [Member]", "label": "QXLShares Member" } } }, "auth_ref": [] }, "cmnd_QXLWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "QXLWarrantsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "QXL Warrants [Member]", "label": "QXLWarrants Member" } } }, "auth_ref": [] }, "cmnd_QuantumXLabsIncSharesAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "QuantumXLabsIncSharesAndWarrantsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Quantum X Labs Inc. - shares and warrants [Member]" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r34", "r56", "r67", "r76", "r118", "r187", "r188", "r218" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r34", "r56", "r67", "r76", "r118", "r187", "r188", "r218" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r76" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]" } } }, "auth_ref": [ "r76" ] }, "ifrs-full_RecurringFairValueMeasurementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RecurringFairValueMeasurementMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring Fair Value Measurement [Member]", "label": "Recurring fair value measurement [member]" } } }, "auth_ref": [ "r50", "r147" ] }, "cmnd_RelatedPartyConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "RelatedPartyConsultantMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Consultant [Member]", "label": "Related Party Consultant Member" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "cmnd_RelatedPartyTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "RelatedPartyTransactionsDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_RelatedPartyTransactionsScheduleofBalanceswithRelatedPartiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "RelatedPartyTransactionsScheduleofBalanceswithRelatedPartiesDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions - Schedule of Balances with Related Parties (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofCompensationtoKeyManagementPersonnelforServicesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions - Schedule of Compensation to Key Management Personnel for Services (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_RentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RentalExpense", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent paid", "label": "Rental expense, operating" } } }, "auth_ref": [ "r228" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Incurred research and development expenses", "terseLabel": "Research and development, net", "label": "Research and development expense" } } }, "auth_ref": [ "r27", "r134" ] }, "ifrs-full_ReserveOfSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfSharebasedPayments", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment reserve (Notes 9, 10)", "label": "Reserve of share-based payments" } }, "en": { "role": { "documentation": "A component of equity resulting from share-based payments." } } }, "auth_ref": [ "r225" ] }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfSharebasedPaymentsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment reserve", "label": "Reserve of share-based payments [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } } }, "auth_ref": [ "r203" ] }, "cmnd_RestrictedShareUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "RestrictedShareUnitMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Units [Member]", "label": "Restricted Share Unit Member" } } }, "auth_ref": [] }, "cmnd_RestrictedShareUnitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "RestrictedShareUnitsAbstract", "lang": { "en-us": { "role": { "label": "Restricted Share Units [Abstract]" } } }, "auth_ref": [] }, "cmnd_RestrictedShareUnitsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "RestrictedShareUnitsDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Share Units (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_RestrictedShareUnitsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestrictedShareUnitsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails", "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Units [Member]", "verboseLabel": "RSUs [Member]", "label": "Restricted share units [member]" } }, "en": { "role": { "documentation": "This member stands for restricted share units." } } }, "auth_ref": [ "r209" ] }, "cmnd_RestrictedShareUnitsScheduleofRSUsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "RestrictedShareUnitsScheduleofRSUsDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Share Units - Schedule of RSUs (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_RestrictedStockFairValueAtIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "RestrictedStockFairValueAtIssuance", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock fair value at issuance (in Dollars)", "label": "Restricted Stock Fair Value At Issuance", "documentation": "Restricted stock fair value at issuance." } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited", "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r200", "r205", "r206" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r158", "r203" ] }, "cmnd_ReverseShareSplitsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ReverseShareSplitsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Reverse share splits [Member]" } } }, "auth_ref": [] }, "cmnd_ReverseSplit": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ReverseSplit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnauditedParentheticals", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse split", "label": "Reverse Split", "documentation": "Reverse split." } } }, "auth_ref": [] }, "cmnd_ReverseStockSplitDescription": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ReverseStockSplitDescription", "presentation": [ "http://clearmindmedicine.com/20260731/role/NatureofOperationsandGoingConcernDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Reverse split", "label": "Reverse Stock Split Description", "documentation": "Reverse stock split, description." } } }, "auth_ref": [] }, "cmnd_RightOfUseAssetsObtainedInExchangeForLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "RightOfUseAssetsObtainedInExchangeForLeaseLiabilities", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use assets obtained in exchange for lease liabilities", "label": "Right Of Use Assets Obtained In Exchange For Lease Liabilities", "documentation": "Amount of right of use assets obtained in exchange for lease liabilities." } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset (Note 14e)", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r58", "r62", "r106" ] }, "cmnd_ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Assets And Liabilities Measured At Fair Value Abstract" } } }, "auth_ref": [] }, "cmnd_ScheduleOfBalancesWithRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfBalancesWithRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Balances With Related Parties Abstract" } } }, "auth_ref": [] }, "cmnd_ScheduleOfBinomialModelWasUsedToMeasureTheDerivativeWarrantLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfBinomialModelWasUsedToMeasureTheDerivativeWarrantLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Abstract]" } } }, "auth_ref": [] }, "cmnd_ScheduleOfChangesInRSUsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfChangesInRSUsTableTextBlock", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of RSUs", "label": "Schedule Of Changes In RSUs Table Text Block", "documentation": "Schedule of Changes in RSUs." } } }, "auth_ref": [] }, "cmnd_ScheduleOfChangesInTheDerivativeWarrantLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfChangesInTheDerivativeWarrantLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Changes in the Derivative Warrant Liability [Abstract]" } } }, "auth_ref": [] }, "cmnd_ScheduleOfChangesInWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfChangesInWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Warrants Abstract" } } }, "auth_ref": [] }, "cmnd_ScheduleOfCompensationToKeyManagementPersonnelForServicesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfCompensationToKeyManagementPersonnelForServicesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Compensation To Key Management Personnel For Services Abstract" } } }, "auth_ref": [] }, "cmnd_ScheduleOfContractualMaturitiesOfFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfContractualMaturitiesOfFinancialLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Contractual Maturities Of Financial Liabilities Abstract" } } }, "auth_ref": [] }, "cmnd_ScheduleOfFairValueOfThePromissoryNotesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfFairValueOfThePromissoryNotesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of The Promissory Notes [Abstract]" } } }, "auth_ref": [] }, "cmnd_ScheduleOfForeignCurrencyAgainstTheFunctionalCurrenciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfForeignCurrencyAgainstTheFunctionalCurrenciesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Foreign Currency Against The Functional Currencies Abstract" } } }, "auth_ref": [] }, "cmnd_ScheduleOfRsusAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfRsusAbstract", "lang": { "en-us": { "role": { "label": "Schedule of RSUs [Abstract]" } } }, "auth_ref": [] }, "cmnd_ScheduleOfShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfShortTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Short Term Investments Abstract" } } }, "auth_ref": [] }, "cmnd_ScheduleOfWarrantsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ScheduleOfWarrantsOutstandingAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrants Outstanding Abstract" } } }, "auth_ref": [] }, "cmnd_SciSparcLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "SciSparcLtdMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SciSparc Ltd [Member]", "label": "Sci Sparc Ltd Member" } } }, "auth_ref": [] }, "cmnd_September2023WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "September2023WarrantsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "September 2023 Warrants [Member]", "label": "September2023 Warrants Member" } } }, "auth_ref": [] }, "cmnd_ShareCapitalDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ShareCapitalDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Share Capital (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansScheduleofFairValueofthePromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares upon conversion of convertible loans", "label": "Share issue related cost" } } }, "auth_ref": [ "r220" ] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital and share premium (Note 7)", "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r200", "r205" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital and share premium", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r158" ] }, "cmnd_SharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "SharePriceMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Price [Member]", "label": "Share Price Member" } } }, "auth_ref": [] }, "cmnd_SharePurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "SharePurchaseAgreementMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Purchase Agreement [Member]", "label": "Share Purchase Agreement Member" } } }, "auth_ref": [] }, "cmnd_SharesExercised": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "SharesExercised", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Shares exercised", "documentation": "The number of shares exercised." } } }, "auth_ref": [] }, "cmnd_ShortTermInvestmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ShortTermInvestmentLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Investments [Line Items]" } } }, "auth_ref": [] }, "cmnd_ShortTermInvestmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ShortTermInvestmentsDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Investments (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_ShortTermInvestmentsScheduleofShortTermInvestmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ShortTermInvestmentsScheduleofShortTermInvestmentsDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Investments - Schedule of Short-Term Investments (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_ShorttermInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ShorttermInvestmentMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investment [Member]", "label": "Shortterm Investment Member" } } }, "auth_ref": [] }, "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents", "crdr": "debit", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investment", "label": "Short-term investments, classified as cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r215" ] }, "ifrs-full_SignificantUnobservableInputLiabilities": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantUnobservableInputLiabilities", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative warrant liability measurement assumptions", "label": "Significant unobservable input, liabilities" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } } }, "auth_ref": [ "r52" ] }, "cmnd_SpaceForOfficesMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "SpaceForOfficesMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Space for Offices [Member]", "label": "Space For Offices Member" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited", "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnauditedParentheticals" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited", "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnauditedParentheticals" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r158" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "cmnd_StockOptionsAwardGrantedVestedTerm": { "xbrltype": "durationItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "StockOptionsAwardGrantedVestedTerm", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options award granted vest term", "label": "Stock Options Award Granted Vested Term", "documentation": "Stock options award granted vested term." } } }, "auth_ref": [] }, "cmnd_StockOptionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "StockOptionsDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Stock Options (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_StockholdersEquityReverseStockSplits": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "StockholdersEquityReverseStockSplits", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity, reverse stock split", "label": "Stockholders Equity Reverse Stock Splits", "documentation": "Stockholders' equity, reverse stock split." } } }, "auth_ref": [] }, "ifrs-full_SubscriptionCirculationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SubscriptionCirculationRevenue", "crdr": "credit", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription amount", "label": "Subscription circulation revenue" } } }, "auth_ref": [ "r222" ] }, "cmnd_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "SubsequentEventsDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_SupplementaryDisclosureOfCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "SupplementaryDisclosureOfCashFlowInformationAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplementary disclosure of cash flow information:", "label": "Supplementary Disclosure Of Cash Flow Information Abstract" } } }, "auth_ref": [] }, "cmnd_TaurusGoldCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "TaurusGoldCorpMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsScheduleofShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taurus Gold Corp. \u2013 shares and warrants [Member]", "label": "Taurus Gold Corp Member" } } }, "auth_ref": [] }, "cmnd_TaurusSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "TaurusSharesMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taurus Shares [Member]", "label": "Taurus Shares Member" } } }, "auth_ref": [] }, "cmnd_TaurusWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "TaurusWarrantsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taurus Warrants [Member]", "label": "Taurus Warrants Member" } } }, "auth_ref": [] }, "cmnd_ThirdPartyInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "ThirdPartyInvestorMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party Investor [Member]", "label": "Third Party Investor Member" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofBinomialModelwasUsedtoMeasuretheDerivativeWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of Range [Member]", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r34", "r56", "r67", "r76", "r118", "r187", "r188", "r218" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToRelatedParties", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 1.0 }, "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails": { "parentTag": "cmnd_ForeignCurrencyFinancialAssetsAndLiabilities", "weight": 1.0, "order": 2.0 }, "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofContractualMaturitiesofFinancialLiabilitiesDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsScheduleofBalanceswithRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Balances with related parties", "netLabel": "Due to related parties", "terseLabel": "Due to related parties (Note 4a)", "label": "Current payables to related parties" } }, "en": { "role": { "documentation": "The amount of current payables due to related parties. [Refer: Total for all related parties [member]; Payables to related parties]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_TradeAndOtherCurrentReceivablesDueFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivablesDueFromRelatedParties", "crdr": "debit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited", "http://clearmindmedicine.com/20260731/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Owed to the company", "terseLabel": "Related parties (Note 4b)", "label": "Current receivables due from related parties" } }, "en": { "role": { "documentation": "The amount of current receivables due from related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r199", "r204" ] }, "ifrs-full_TradingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradingIncomeExpenseAbstract", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Trading income (expense) [abstract]" } } }, "auth_ref": [] }, "cmnd_TwoThousandTwentyFiveTaurusWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "TwoThousandTwentyFiveTaurusWarrantMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "2025 Taurus Warrant [Member]" } } }, "auth_ref": [] }, "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfAntidilutiveInstrumentsAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetails", "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails", "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofChangesinWarrantsDetails", "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Types of antidilutive instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r23" ] }, "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfAntidilutiveInstrumentsDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetails", "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsDetails", "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails", "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails", "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails", "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofChangesinWarrantsDetails", "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Types of antidilutive instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used." } } }, "auth_ref": [ "r23" ] }, "ifrs-full_TypesOfContractsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails", "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "label": "Types of contracts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r189", "r191", "r198" ] }, "ifrs-full_TypesOfContractsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails", "http://clearmindmedicine.com/20260731/role/ConvertibleLoansDetails" ], "lang": { "en-us": { "role": { "label": "Types of contracts [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } } }, "auth_ref": [ "r189", "r191", "r198" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesParentheticalsDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r8", "r68", "r69", "r70", "r71", "r81", "r85", "r86", "r126" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesDetails", "http://clearmindmedicine.com/20260731/role/FinancialInstrumentsandRiskManagementScheduleofForeignCurrencyAgainsttheFunctionalCurrenciesParentheticalsDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r8", "r68", "r69", "r70", "r71", "r81", "r85", "r86", "r126" ] }, "cmnd_WarrantExercisedCommonShare": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "WarrantExercisedCommonShare", "presentation": [ "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercised common shares", "label": "Warrant Exercised Common Share", "documentation": "Warrant exercised common share." } } }, "auth_ref": [] }, "cmnd_WarrantExpireTerm": { "xbrltype": "dateItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "WarrantExpireTerm", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants expire", "label": "Warrant Expire Term", "documentation": "Warrants expire term." } } }, "auth_ref": [] }, "cmnd_WarrantExpiryDate": { "xbrltype": "dateItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "WarrantExpiryDate", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiry date", "label": "Warrant Expiry Date", "documentation": "Expiry date of share purchase warrants." } } }, "auth_ref": [] }, "ifrs-full_WarrantReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantReserve", "crdr": "credit", "calculation": { "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofFinancialPositionUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants (Note 8)", "label": "Warrant reserve" } }, "en": { "role": { "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]" } } }, "auth_ref": [ "r225" ] }, "cmnd_WarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "WarrantsExercised", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued", "label": "Warrants Exercised", "documentation": "The number of warrants exercised." } } }, "auth_ref": [] }, "cmnd_WarrantsExercisedIntoCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "WarrantsExercisedIntoCommonShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercised", "label": "Warrants Exercised Into Common Shares", "documentation": "Number of warrants exercised into common shares." } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimStatementsofChangesinShareholdersEquityUnaudited", "http://clearmindmedicine.com/20260731/role/DerivativeWarrantLiabilitiesScheduleofChangesintheDerivativeWarrantLiabilityDetails", "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofChangesinWarrantsDetails", "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "netLabel": "Warrants [member]", "verboseLabel": "Warrants [Member]", "terseLabel": "Warrants", "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r209" ] }, "cmnd_WarrantsScheduleofChangesinWarrantsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "WarrantsScheduleofChangesinWarrantsDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofChangesinWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants - Schedule of Changes in Warrants (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_WarrantsScheduleofWarrantsOutstandingDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "WarrantsScheduleofWarrantsOutstandingDetailsTable", "presentation": [ "http://clearmindmedicine.com/20260731/role/WarrantsScheduleofWarrantsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants - Schedule of Warrants Outstanding (Details) [Table]" } } }, "auth_ref": [] }, "cmnd_WarrantssMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "WarrantssMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Member]", "label": "Warrantss Member" } } }, "auth_ref": [] }, "ifrs-full_WarrantyProvisionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantyProvisionAbstract", "lang": { "en-us": { "role": { "label": "Warrants [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average issue price, Exercised", "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r217" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average issue price, Granted", "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r217" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://clearmindmedicine.com/20260731/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price", "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r74", "r75", "r138", "r139" ] }, "cmnd_WeightedAverageIssuePrice": { "xbrltype": "perShareItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "WeightedAverageIssuePrice", "presentation": [ "http://clearmindmedicine.com/20260731/role/RestrictedShareUnitsScheduleofRSUsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average issue price, Ending Balance", "periodStartLabel": "Weighted average issue price, Beginning balance", "label": "Weighted Average Issue Price", "documentation": "Weighted average issue price." } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://clearmindmedicine.com/20260731/role/CondensedInterimConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding for the purposes of basic loss per share", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r22" ] }, "cmnd_YissumMetabolicSyndromeLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "YissumMetabolicSyndromeLicenseAgreementMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yissum Metabolic Syndrome License Agreement [Member]", "label": "Yissum Metabolic Syndrome License Agreement Member" } } }, "auth_ref": [] }, "cmnd_YissumPTSDLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "YissumPTSDLicenseAgreementMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yissum PTSD License Agreement [Member]", "label": "Yissum PTSDLicense Agreement Member" } } }, "auth_ref": [] }, "cmnd_YissumPsychedelicLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://clearmindmedicine.com/20260731", "localname": "YissumPsychedelicLicenseAgreementMember", "presentation": [ "http://clearmindmedicine.com/20260731/role/CommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yissum Psychedelic License Agreement [Member]", "label": "Yissum Psychedelic License Agreement Member" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H_b&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M_b&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_a&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_b&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "34", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66_b&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71_b&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "72", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_a&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_d&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }